Selexis SA to Speak on Fc Fusion Proteins at the 2011 European Society for Animal Cell Technology (ESACT) Conference

Published: Apr 20, 2011

Geneva, Switzerland (PRWEB) April 20, 2011 – Selexis SA, a Swiss-based biotechnology company with technologies for the rapid development and engineering of high yield and stable mammalian cell lines for therapeutic protein manufacturing of recombinant drugs announced today the Company’s Chief Scientific Officer, Pierre-Alain Girod, PhD, will be speaking on Fc Fusion Proteins at the 2011 ESACT Meeting on May 15, 2011 at the Hofburg Congress Center in Vienna.

Dr. Girod will be speaking in workshop titled, “Fc Fusion Proteins: A Growing Class of Therapeutics” on:

Sunday, May 15, 14:00 – 15:45. Registration for the workshop is required.

Workshop Abstract:

The potential therapeutic value of many proteins—including enzymes, cell-surface receptors, cytokines and peptides—can be realized by fusing these proteins to the Fc region of human immunoglobulin G. Of the 30 MAb products approved as human therapeutics in the USA to date, 4 are Fc fusion proteins, and many more are in clinical testing. Considerations in fusion protein design and production will be presented.

Companies or individuals attending the conference can register for the EASCT meeting by visiting:

About Selexis SA

Headquartered in Geneva, Switzerland, Selexis SA is a privately held biotechnology company dedicated to the development of innovative technologies and world-class expert services that significantly reduce the time, effort, and costs associated with developing high-performance mammalian cell lines for therapeutic protein production (i.e. MAbs, growth factors, enzymes). The Company's SURE Cell Line Development™ Technology Platform is based on Selexis Genetic Elements™ -- novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. The technology platform also includes Selexis SUREtech Vectors™, Selexis SUREfection™ Transfection Methods, Selexis SUREvarient Screening™ and the proprietary Selexis SURECHO-M Cell Line™.

For more information, visit

Back to news